1-5 of 5
Surita Dalal, PhD
Close
Sort by
Journal Articles

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Andy C. Rawstron, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Shanna Maycock, BSc, MSc, Nichola Webster, Kristian Brock, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Francesca Yates, PhD, Rebecca Jarvis, BSc, Surita Dalal, PhD, Ruth M. de Tute, PhD FRCPath, Paul Moss, MBBS, PhD FRCP, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Piers Patten, MD PhD, Christopher Fegan, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, Christopher P. Fox, MD PhD, Adrian Bloor, PhD FRCP, FRCPath, Oonagh Sheehy, MB BCh BAO, MRCP, FRCPath, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-136990
Published: 2020
Journal Articles

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Nichola Webster, Surita Dalal, PhD, Kristian Brock, PhD, Francesca Yates, PhD, Chhaya Sankhalpara, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Christopher Fegan, Alison McCaig, MBChB, FRCPath, PhD MRCP, Anna Schuh, MD MRCP, PhD, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Piers Patten, MD PhD, Stephen Devereux, PhD FRCP, FRCPath, MRCPath, MB BS, Adrian Bloor, PhD FRCP, FRCPath, Christopher P Fox, PhD FRCPath, MRCP, MBChB, Francesco Forconi, MD PhD FRCPath, Andrew Rawstron, PhD, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-136960
Published: 2020
Journal Articles

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure

Andy Rawstron, PhD, Talha Munir, Kristian Brock, MSc, BSc, Nichola Webster, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Sophie Cramp, MSc, BSc, Rebecca Bishop, BSc, Surita Dalal, PhD, Ruth M De Tute, BSc,MSc, Oonagh Sheehy, Andrew Pettitt, FRCPath, PhD, Christopher P. Fox, MD PhD, Stephen Devereux, PhD, Christopher Fegan, MD, Donald MacDonald, Adrian Bloor, MA MB BChir PhDFCRP FRCPath, Peter Hillmen, MB ChB, PhD FRCP, FRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 181.
https://doi.org/10.1182/blood-2018-181
Published: 2018
Journal Articles

BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia

Marwan Kwok, MBBS,MRCP, Andy Rawstron, PhD, Angelo Agathanggelou, PhD, Anshita Goel, PhD, Ceri Oldreive, PhD, Rhiannon E Jones, PhD, Samantha Drennan, PhD, Archana Sharma-Oates, PhD, Paul Evans, PhD, Edward Smith, MSc, Jingwen Mao, Jamie Beaumont, Jusveen Rai, Mayumi Hamada, MB ChB, Surita Dalal, PhD, Naheema Gordon, MSc, Nicholas Davies, PhD, Helen Parry, MB ChB, MRCP, PhD, Andrew Beggs, MBBS, PhD FRCS, Talha Munir, Paul Moreton, MD MRCP, FRCPath, Shankara Paneesha, MD MRCP, FRCPath, Guy Pratt, MD FRCP, FRCPath, Malcolm Taylor, PhD, Francesco Forconi, MD DM, PhD FRCPath, Duncan M Baird, PhD, Jean-Baptiste Cazier, PhD, Paul Moss, MBBS, PhD FRCP, Peter Hillmen, MBChB, PhD, Tatjana Stankovic, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3004.
https://doi.org/10.1182/blood.V130.Suppl_1.3004.3004
Published: 2017
Journal Articles

The Bloodwise TAP Calibre Feasibility Study to Assess the Mechanism of Action of Idelalisib in B-Cell Receptor Pathway (BCR) Inhibition in Chronic Lymphocytic Leukaemia (CLL)

Talha Munir, Peter Hillmen, MBChB, PhD, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz-Vicente, Francesca Yates, PhD, Surita Dalal, PhD, Ruth M de Tute, PhD FRCPath, Chris P Fox, Donald Macdonald, Christopher Fegan, MD, Adrian Bloor, Anna Schuh, MD PhD, Gina Doody
Journal: Blood
Blood (2017) 130 (Supplement 1): 3014.
https://doi.org/10.1182/blood.V130.Suppl_1.3014.3014
Published: 2017